Andrew Witty: Volume is Not a Dirty Word
“Volume is not a dirty word” was outgoing GSK head Sir Andrew Witty’s key message at last week’s FT Global Pharmaceutical Conference in London.
The Cancer Care Conundrum in Europe
Cancer treatment is an increasing dilemma for EU health services as they try to balance patient care against budgetary constraints.
Has Gastein Peaked?
This year’s 19th annual European Health Forum Gastein (Austria) once again attempted to establish unity in the face of EU woes. But are the Gastein region’s “healing powers” on the wane?
Pharmaceutical Executive, November 2016 Issue (PDF)
Click the title above to open the Pharmaceutical Executive November 2016 issue in an interactive PDF format.
PE Media Planner 2017
New Challenge to IP Innovation
Survey on the rising use of Inter Partes Reviews to challenge patents reveals key considerations for originator companies.
Major Changes Ahead for Drug User Fees
PDUFA VI to enhance FDA staffing, revise fees and expand evidence for drug development.
Pharmaceutical Executive, October 2016 Issue (PDF)
Click the title above to open the Pharmaceutical Executive October 2016 issue in an interactive PDF format.
Managing Medication Adherence to Improve Clinical Trial Quality
CETA in the Balance
Can pharma help to salvage the EU's Comprehensive Economic and Trade Agreement with Canada in the face of resistance? Reflector reports.
New GSK Chief Will Be "Most Powerful" UK Female CEO
Emma Walmsley will succeed Andrew Witty next year and become the seventh female chief executive in the FTSE 100.
Pharmaceutical Executive, September 2016 Issue (PDF)
Click the title above to open the Pharmaceutical Executive September 2016 issue in an interactive PDF format.
On and Off the Pharma Podium
In the spirit of the Olympics, we cite some of the feel-good and not-so-good stories making waves in the competitive world of pharma.
European Pharma and the Unified Patent Court
A look at the EU plans for a European patent, and where the UK fits in the mix.
An EU Referendum ... on Drug Pricing?
The chances are slim, but a new resolution in Europe on the subject could drum up support for a Brexit-like scenario.
Pharmaceutical Executive, August 2016 Issue (PDF)
Click the title above to open the Pharmaceutical Executive August 2016 issue in an interactive PDF format.
Stem Cell Therapies Still Facing Commercial Challenges
July 22, 2016
Assuring Trust in the Digital Space
Accelerating the Drive for New Antibiotics
Time for new pharma strategies to combat deadly drug-resistant infections
Pharmaceutical Executive, July 2016 Issue (PDF)
Click the title above to open the Pharmaceutical Executive July 2016 issue in an interactive PDF format.
“Have We Met Your Needs Today?” Patient Centricity is So Much More than a Customer Satisfaction Survey
In the healthcare industry, “patient centricity” is like comfort food – everyone knows what it is, but it can mean very different things to different people.
Transforming Commercial Models in the Pharmaceutical Industry
In this paper, we’ll explore opportunities pharma marketers have to create engaging experiences that will deliver new types of value to meet their targets’ evolving expectations.
Medication Adherence Packaging Technology
Transforming Commercial Models
Pharma Failing to Address Corruption Risks, Says Report
Policy makers "simply are not taking seriously the corrosive effect of corruption", study says.
Europe’s ‘Radical’ Regulators Drawn Further into Pricing Debate
Top officials at EMA push the boat out on drug-pricing views.
Pharmaceutical Executive, June 2016 Issue (PDF)
Click the title above to open the Pharmaceutical Executive June 2016 issue in an interactive PDF format.
Pharma Under Pressure to Curb Opioid Abuse
Policymakers seek to limit prescribing while also encouraging innovative R&D.
Pharmaceutical Executive, May 2016 Issue (PDF)
Click the title above to open the Pharmaceutical Executive May 2016 issue in an interactive PDF format.
Episode 2: How On-Dose Technologies Mitigate Safety Risks and Reduce Product Diversion and Counterfeiting
